This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: dyslipidaemia

January 2019 Br J Cardiol 2019;26:35 doi:10.5837/bjc.2019.005 Online First

Association of subclinical hypothyroidism in heart failure: a study from South India

Pramod Kumar Kuchulakanti, VCS Srinivasarao Bandaru, Anurag Kuchulakanti, Tallapaneni Lakshumaiah, Mehul Rathod, Rajeev Khare, Parsa Sairam, Poondru Rohit Reddy, Athuluri Ravikanth, Avvaru Guruprakash, Regalla Prasada Reddy, Banda Balaraju

Abstract

Introduction Heart failure (HF) is a complex disease, characterised by the reduced capacity of the heart to pump blood, supply or fill with blood, and is a cause of hospitalisation.1 HF is rapidly growing in developed and developing countries, with an estimated prevalence of more than 37 million individuals.2 HF is associated with a high rate of hospitalisation and it is a major cause of morbidity and mortality worldwide.1-3 Existing studies have shown that several comorbid factors and biomarkers are associated with HF and its prognosis.4 Recent studies have associated subclinical hypothyroidism with increased blood pressure, insulin resistan

| Full text
Optimising cardiovascular risk reduction in diabetes

September 2018 Br J Cardiol 2018;25(suppl 2):S19–S26 doi:10.5837/bjc.2018.s10

Optimising cardiovascular risk reduction in diabetes

W David Strain

Abstract

Introduction Throughout this supplement, there has been discussion of the epidemiology of cardiovascular disease within people with diabetes, and a focus on the management of glycaemia. Given that the majority of people with diabetes ultimately die a premature cardiovascular death, diabetes management has become synonymous with cardiovascular risk reduction. However, since the United Kingdom Prospective Diabetes Study (UKPDS),1 it has become increasingly clear that the multi-factorial nature of diabetes requires a multi-factorial approach. Initially, much of this was extrapolated from existing cardiovascular data, with diabetes just being re

| Full text
Targeting residual risk: a new approach to treating CVD?

July 2014 Br J Cardiol 2014;21:108–12 doi:10.5837/bjc.2014.023

Targeting residual risk: a new approach to treating CVD?

Alan Begg, Iain Findlay

Abstract

Introduction Atherosclerosis is a systemic disease of the large- and medium-sized muscular arteries, which is characterised by endothelial dysfunction, vascular inflammation, and the build up of lipids, cholesterol, calcium, and cellular debris within the intima of the vessel wall. This build up results in plaque formation, vascular remodelling, acute and chronic luminal obstruction, abnormalities of blood flow and diminished oxygen supply to target organs.1 Plaque rupture and thrombosis result in the acute clinical complications of atherosclerosis. The process of atherosclerosis begins early in life and progresses over many decades. Rupture

| Full text

June 2014 Br J Cardiol 2014;21:51

Correspondence: assessing the clinical benefits of drugs for dyslipidaemia

Gilbert Wagener

Abstract

Assessing the clinical benefits of drugs for dyslipidaemia Dear Sirs, A recent editorial in the New England Journal of Medicine1 highlights several challenging issues in the development of new treatments for lipid disorders. There is now uncertainty regarding the regulatory approach of approving drugs on the basis of favourable lipid effects and evaluating clinical benefit after approval. In numerous trials and several meta-analyses of outcome trials, the reduction of low-density lipoprotein (LDL) cholesterol has been shown to be associated with outcome benefit.2–4 Most of these studies have been performed with statins. The first demonstrat

| Full text
The future of CETP inhibition – still to be REVEALed

August 2012 Br J Cardiol 2012;19:104–06 doi:10.5837/bjc.2012.022

The future of CETP inhibition – still to be REVEALed

Jonathan Morrell

Abstract

Reducing the residual cardiovascular risk that remains after statin use is a frontline challenge for preventive cardiology. After attention to other modifiable risk factors, further reduction of low-density lipoprotein cholesterol (LDL-C) levels and increasing high-density lipoprotein cholesterol (HDL-C) levels are under particular scrutiny.1,2 The cardioprotective epidemiology of HDL-C is strong and well known, and so it often comes as a shock to health professionals that there is no direct proof that raising HDL-C improves cardiovascular outcomes. Despite this, raising HDL-C remains an attractive potential approach for tackling residual ris

| Full text
In brief

August 2012 Br J Cardiol 2012;19:112–3

In brief

BJCardio Staff

Abstract

EVINCI study completed The prevalence of “significant” coronary artery disease in patients with chest pain symptoms is lower than expected in Europe, according to preliminary findings from the The EValuation of INtegrated Cardiac Imaging (EVINCI) study. Once the final analysis is completed, the EVINCI study is expected to demonstrate that performing adequate non-invasive imaging screening of patients with suspected coronary artery disease could safely avoid invasive procedures in 75 out of 100 patients.  The study will have sufficient power to answer the question of which is the most cost-effective non-invasive imaging strategy for the j

| Full text

July 2008 Br J Cardiol 2008;15:210-14

Clinical experience with prolonged-release nicotinic acid in statin-treated patients managed in Ireland

Michael O’Reilly, Ulrike Hostalek, John Kastelein

Abstract

Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab

| Full text

July 2006 Br J Cardiol 2006;13:273-7

Safety and tolerability of prolonged-release nicotinic acid combined with a statin in NAUTILUS

Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen, on behalf of the NAUTILUS Study Group

Abstract

No content available

| Full text

July 2006 Br J Cardiol 2006;13:278-82

Safety and tolerability of prolonged-release nicotinic acid in patients aged > 65 years enrolled in NAUTILUS

Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen, on behalf of the NAUTILUS Study Group

Abstract

No content available

| Full text

May 2006 Br J Cardiol 2006;13:205-208

Do fibrates offer special benefits in treating diabetic dyslipidaemia? Lessons from FIELD

Hugh F McIntyre

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now